Consensus Ocugen, Inc.

Stocks

OCGN

US67577C1053

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-16 EDT			5-day change	1st Jan Change
0.7803 ^USD	-4.10%		-18.34%	-42.20%

09-14	Ocugen Insider Sold Shares Worth $589,110, According to a Recent SEC Filing	MT
09-01	Ocugen Doses First Patient in Trial of Potential Eye Disease Drug	MT

Evolution of the Average Target: Ocugen, Inc.

Evolution of the Target Price: Ocugen, Inc.

Changes in Analyst Recommendations: Ocugen, Inc.

ea5b5b1441fdbbb12b.sbkcWpxt93EP347XFWfkX0ZB8yKG7ME33S5EVZ9R_5I.8vVsL8Q0xBpHgOS6YFSXHAQ7xnb8uIZR6WUIIdIDzPTp2k8driSRXD2Jxw~8bb12b44e3ccabbb224a9932b5cec192

Analysts' recommendations: Ocugen, Inc.

04-10	Ocugen, Inc. Announces Modifier Gene Therapy Delivers 46% Lesion Reduction in Age-Related Macular Degeneration	CI
03-17	Canaccord Genuity Initiates Ocugen at Buy With $12 Price Target	MT
03-11	Top Midday Gainers	MT
03-11	Oppenheimer Initiates Ocugen at Outperform With $10 Price Target	MT
25-03-06	Chardan Capital Adjusts Ocugen Price Target to $7 From $6, Maintains Buy Rating	MT
24-04-22	Chardan Adjusts Price Target on Ocugen to $5 From $4, Maintains Buy Rating	MT
24-04-22	Chardan Raises Price Target on Ocugen to $5 From $4, Keeps Buy Rating	MT
24-01-24	HC Wainwright Adjusts Price Target on Ocugen to $7 From $5, Maintains Buy Rating	MT
23-08-31	Cantor Fitzgerald Adjusts Ocugen's Price Target to $2 From $2.50, Keeps Overweight Rating	MT
23-05-08	Chardan Research Raises Ocugen's Price Target to $4 From $3.50, Buy Rating Kept	MT
23-03-01	Chardan Upgrades Ocugen to Buy From Neutral, Citing Recent Sell-Off	MT
23-03-01	Mizuho Adjusts Price Target on Ocugen to $3 From $5, Maintains Buy Rating	MT
22-08-23	Mizuho Securities Starts Ocugen at Buy With $5 Price Target	MT
22-08-15	HC Wainwright Adjusts Ocugen's Price Target to $6 from $7, Maintains Buy Rating	MT
22-06-15	Roth Capital Reinstates Ocugen at Buy with $8 Price Target	MT
22-06-02	Cantor Fitzgerald Starts Ocugen at Overweight With $4.50 Price Target	MT
22-05-09	Chardan Trims Ocugen's Price Targe to $3.50 From $4, Maintains Neutral Rating	MT
22-05-09	Chardan Research Adjusts Ocugen's Price Target to $3.50 From $4, Maintains Neutral Rating	MT
22-02-28	HC Wainwright Adjusts Ocugen's Price Target to $8 from $10, Maintains Buy Rating	MT
21-06-14	Analyst recommendations: Alliant Energy, Ally Financial, Alphabet, HSBC, Honest...
21-06-11	Ocugen : Chardan Adjusts Ocugen PT to $4.50 From $8, Maintains Neutral Rating	MT
21-06-11	Ocugen : Cantor Fitzgerald Adjusts Ocugen PT to $4 From $11, Maintains Neutral Rating	MT
21-06-11	Ocugen : HC Wainwright Adjusts Ocugen's Price Target to $10 From $12, Maintains Buy Rating	MT
21-06-11	Ocugen : Roth Capital Cuts Ocugen to Neutral From Buy, Price Target to $6 From $10	MT
21-05-10	Ocugen : Chardan Adjusts Price Target on Ocugen to $8 From $13, Maintains Neutral Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	OCUGEN, INC.					+1,459.23%
	WUXI APPTEC CO., LTD.					+32.97%
	LONZA GROUP AG					+14.74%
	ARGENX SE					+38.45%
	IQVIA HOLDINGS INC.					+12.07%
	BEONE MEDICINES AG					+18.26%
	REVOLUTION MEDICINES, INC.					+44.87%
	CELLTRION, INC.					+38.06%
	WUXI BIOLOGICS (CAYMAN) INC.					+24.78%
	GENMAB A/S					+8.87%
	Average					+169.23%
	Weighted average by Cap.					+27.77%